The Fiji Kava Ltd (ASX: FIJ) share price soared 89.66% higher this morning to reach an intraday high of 16.5 cents. This came before the Fiji Kava share price pulled back to 12.5 cents and was placed in a trading pause, pending a further announcement. The commotion resulted from the company’s announcement it has signed a major agreement with BioCeuticals, a company owned by Blackmores Limited (ASX: BKL).
Fiji Kava produces natural ‘noble kava’ products for the complementary and alternative medicine market which is estimated to exceed US$210 billion by 2026 globally. It is focused on providing an alternative to prescription medications to promote sleep, soothe and calm the nerves, support muscle relaxation and relax the mind. The products are Theapeutic Goods Administration (TGA) and Food and Drug Administration (FDA) compliant.
Major agreement highlights
Fiji Kava has announced a non-exclusive licence agreement with BioCeuticals to develop a co-branded product for release in Australia and New Zealand. It will see BioCeuticals use the noble kava extract for its AnxioCalm product. AnxioCalm is a herbal medicine to support symptomatic relief of mild anxiety, tension and stress.
In addition, AnxioCalm products will be co-branded with Fiji Kava’s ‘Authentic Fiji Kava’ trademark on each product sold. It will be made available through BioCeuticals’ extensive network of qualified healthcare practitioners across Australia and New Zealand.
The agreement follows progress being made on Fiji Kava’s commercial strategy to grow the availability of its Fijian noble kava. It now has cornerstone retail agreements with Coles Group Ltd (ASX: COL) supermarkets in Australia, Green Cross Pharmacy in New Zealand and has also expanded its eCommerce presence on Amazon.com in the United States. Additionally, it is exploring opportunities to access Chinese marketplaces.
Fiji Kava will supply BioCeuticals with noble kava via its agreement with Pathway International.
Understandably, Fiji Kava founder and CEO, Zane Yoshida, was pleased and said:
“This is another milestone for the company that will not only increase the availability of our noble kava in Australia and New Zealand, but is another strong endorsement by a leading healthcare provider of the quality and uniqueness of our Fijian noble kava…
Fiji Kava will continue to scale-up its production in Fiji to produce required inventory to meet the growing demand from the BioCeuticals licence agreement and other recent business development advancements such as ranging in Coles Supermarkets nationally”.
About the Fiji Kava share price
Before the pause in trade, the Fiji Kava share price was trading at 12.5 cents, representing a 43.68% increase in today’s trade. It has a market capitalisation of around $12 million.
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Amazon and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon. The Motley Fool Australia owns shares of and has recommended Blackmores Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET. The Motley Fool Australia has recommended Amazon. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why the BNK Banking share price jumped 14% today – August 28, 2020 4:57pm
- Marley Spoon share price on watch after upgrading revenue guidance – August 27, 2020 5:34pm
- Mach7 Technologies share price is up 5% on first full year profit result – August 27, 2020 3:33pm